UroGen Pharma (URGN) PT Lowered to $21 at Oppenheimer on Slower Jelmyto Launch, Reiterates Outperform Rating, Sees Situation Improving in 2022 and Beyond

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. STUB
6. EAT
7. NVDA
8. WYFI
9. ARX
10. BTGO

Go back to UroGen Pharma (URGN) PT Lowered to $21 at Oppenheimer on Slower Jelmyto Launch, Reiterates Outperform Rating, Sees Situation Improving in 2022 and Beyond
(NASDAQ: URGN) Delayed: 47.95 -1.05 (2.14%)
Previous Close $49.00    52 Week High $ 
Open $49.60    52 Week Low $ 
Day High $49.60    P/E N/A 
Day Low $47.67    EPS $ 
Volume 670,266